Download PDF
Thorac Cardiovasc Surg 2018; 66(04): 278-286
DOI: 10.1055/s-0036-1583525
Review Article
Georg Thieme Verlag KG Stuttgart · New York

The Value of Circulating Biomarkers in Bicuspid Aortic Valve-Associated Aortopathy

Shiho Naito
1   Department of Cardiac Surgery, Central Hospital Bad Berka, Bad Berka, Germany
,
Mathias Hillebrand
2   Department of Cardiology, University Heart Center Hamburg, Hamburg, Germany
,
Alexander Martin Justus Bernhardt
3   Department of Cardiovascular Surgery, University Heart Center Hamburg, Hamburg, Germany
,
Annika Jagodzinski
2   Department of Cardiology, University Heart Center Hamburg, Hamburg, Germany
,
Lenard Conradi
3   Department of Cardiovascular Surgery, University Heart Center Hamburg, Hamburg, Germany
,
Christian Detter
3   Department of Cardiovascular Surgery, University Heart Center Hamburg, Hamburg, Germany
,
Karsten Sydow
2   Department of Cardiology, University Heart Center Hamburg, Hamburg, Germany
,
Hermann Reichenspurner
3   Department of Cardiovascular Surgery, University Heart Center Hamburg, Hamburg, Germany
,
Yskert von Kodolitsch
2   Department of Cardiology, University Heart Center Hamburg, Hamburg, Germany
,
Evaldas Girdauskas
3   Department of Cardiovascular Surgery, University Heart Center Hamburg, Hamburg, Germany
› Author Affiliations
Further Information

Publication History

06 January 2016

14 March 2016

Publication Date:
05 May 2016 (online)

    Permissions and Reprints All articles of this category

Abstract

Traditional risk stratification model of bicuspid aortic valve (BAV) aortopathy is based on measurement of maximal cross-sectional aortic diameter, definition of proximal aortic shape, and aortic stiffness/elasticity parameters. However, conventional imaging-based criteria are unable to provide reliable information regarding the risk stratification in BAV aortopathy, especially considering the heterogeneous nature of BAV disease. Given those limitations of conventional imaging, there is a growing clinical interest to use circulating biomarkers in the screening process for thoracic aortic aneurysms as well as in the risk-assessment algorithms. We aimed to systematically review currently available biomarkers, which may be of value to predict the natural evolution of aortopathy in individuals with BAV.

Keywords

bicuspid aortic valve - aortopathy - biomarkers
 

  • References

  • 1 Basso C, Boschello M, Perrone C. , et al. An echocardiographic survey of primary school children for bicuspid aortic valve. Am J Cardiol 2004; 93 (05) 661-663
    CrossrefPubMedGoogle Scholar
  • 2 Nistri S, Basso C, Marzari C, Mormino P, Thiene G. Frequency of bicuspid aortic valve in young male conscripts by echocardiogram. Am J Cardiol 2005; 96 (05) 718-721
    CrossrefPubMedGoogle Scholar
  • 3 Panayotova R, Macnab A, Waterworth PD. A pilot project of familial screening in patients with bicuspid aortic valve disease. J Heart Valve Dis 2013; 22 (02) 150-155
    PubMedGoogle Scholar
  • 4 Tutar E, Ekici F, Atalay S, Nacar N. The prevalence of bicuspid aortic valve in newborns by echocardiographic screening. Am Heart J 2005; 150 (03) 513-515
    CrossrefPubMedGoogle Scholar
  • 5 Fedak PWM, Verma S, David TE, Leask RL, Weisel RD, Butany J. Clinical and pathophysiological implications of a bicuspid aortic valve. Circulation 2002; 106 (08) 900-904
    CrossrefPubMedGoogle Scholar
  • 6 Girdauskas E, Borger MA, Secknus M-A, Girdauskas G, Kuntze T. Is aortopathy in bicuspid aortic valve disease a congenital defect or a result of abnormal hemodynamics? A critical reappraisal of a one-sided argument. Eur J Cardiothorac Surg 2011; 39 (06) 809-814
    CrossrefPubMedGoogle Scholar
  • 7 Hiratzka LF, Bakris GL, Beckman JA. , et al; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines; American Association for Thoracic Surgery; American College of Radiology; American Stroke Association; Society of Cardiovascular Anesthesiologists; Society for Cardiovascular Angiography and Interventions; Society of Interventional Radiology; Society of Thoracic Surgeons; Society for Vascular Medicine. 2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM guidelines for the diagnosis and management of patients with Thoracic Aortic Disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, American Association for Thoracic Surgery, American College of Radiology, American Stroke Association, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of Thoracic Surgeons, and Society for Vascular Medicine. Circulation 2010; 121 (13) e266-e369
    CrossrefPubMedGoogle Scholar
  • 8 Erbel R, Aboyans V, Boileau C. , et al; ESC Committee for Practice Guidelines; The Task Force for the Diagnosis and Treatment of Aortic Diseases of the European Society of Cardiology (ESC). 2014 ESC Guidelines on the diagnosis and treatment of aortic diseases: document covering acute and chronic aortic diseases of the thoracic and abdominal aorta of the adult. Eur Heart J 2014; 35 (41) 2873-2926
    CrossrefPubMedGoogle Scholar
  • 9 Svensson LG, Adams DH, Bonow RO. , et al. Aortic valve and ascending aorta guidelines for management and quality measures. Ann Thorac Surg 2013; 95 (6, Suppl): S1-S66
    CrossrefPubMedGoogle Scholar
  • 10 von Kodolitsch Y, Robinson P, Berger J. When should surgery be performed in Marfan syndrome and other connective tissue disorders to protect against type a dissection?. In: Bonser RS, Pagano D, Haverich A, Mascaro J. eds. Controversies in Aortic Dissection and Aneurysmal Disease. London: Springer; 2014: 17-47
    Google Scholar
  • 11 Charitos EI, Stierle U, Petersen M. , et al. The fate of the bicuspid valve aortopathy after aortic valve replacement. Eur J Cardiothorac Surg 2014; 45 (05) e128-e135
    Google Scholar
  • 12 Itagaki S, Chikwe JP, Chiang YP, Egorova NN, Adams DH. Long-term risk for aortic complications after aortic valve replacement in patients with bicuspid aortic valve versus Marfan syndrome. J Am Coll Cardiol 2015; 65 (22) 2363-2369
    CrossrefPubMedGoogle Scholar
  • 13 Pape LA, Tsai TT, Isselbacher EM. , et al; International Registry of Acute Aortic Dissection (IRAD) Investigators. Aortic diameter >or = 5.5 cm is not a good predictor of type A aortic dissection: observations from the International Registry of Acute Aortic Dissection (IRAD). Circulation 2007; 116 (10) 1120-1127
    CrossrefPubMedGoogle Scholar
  • 14 von Kodolitsch Y, Rybczynski M, Bernhardt A. , et al. Marfan syndrome and the evolving spectrum of heritable thoracic aortic disease: do we need genetics for clinical decisions?. Vasa 2010; 39 (01) 17-32
    CrossrefPubMedGoogle Scholar
  • 15 Borger MA, Preston M, Ivanov J. , et al. Should the ascending aorta be replaced more frequently in patients with bicuspid aortic valve disease?. J Thorac Cardiovasc Surg 2004; 128 (05) 677-683
    Google Scholar
  • 16 Della Corte A, Bancone C, Dialetto G. , et al. The ascending aorta with bicuspid aortic valve: a phenotypic classification with potential prognostic significance. Eur J Cardiothorac Surg 2014; 46 (02) 240-247 , discussion 247
    CrossrefPubMedGoogle Scholar
  • 17 Nistri S, Grande-Allen J, Noale M. , et al. Aortic elasticity and size in bicuspid aortic valve syndrome. Eur Heart J 2008; 29 (04) 472-479
    CrossrefPubMedGoogle Scholar
  • 18 Rylski B, Branchetti E, Bavaria JE. , et al. Modeling of predissection aortic size in acute type A dissection: more than 90% fail to meet the guidelines for elective ascending replacement. J Thorac Cardiovasc Surg 2014; 148 (03) 944-8.e1
    CrossrefPubMedGoogle Scholar
  • 19 Girdauskas E, Rouman M, Disha K. , et al. Aortic dissection after previous aortic valve replacement for bicuspid aortic valve disease. J Am Coll Cardiol 2015; 66 (12) 1409-1411
    CrossrefPubMedGoogle Scholar
  • 20 Della Corte A, Bancone C, Quarto C. , et al. Predictors of ascending aortic dilatation with bicuspid aortic valve: a wide spectrum of disease expression. Eur J Cardiothorac Surg 2007; 31 (03) 397-404 , discussion 404–405
    CrossrefPubMedGoogle Scholar
  • 21 Fazel SS, Mallidi HR, Lee RS. , et al. The aortopathy of bicuspid aortic valve disease has distinctive patterns and usually involves the transverse aortic arch. J Thorac Cardiovasc Surg 2008; 135 (04) 901-907 , 907.e1–907.e2
    Google Scholar
  • 22 Schaefer BM, Lewin MB, Stout KK. , et al. The bicuspid aortic valve: an integrated phenotypic classification of leaflet morphology and aortic root shape. Heart 2008; 94 (12) 1634-1638
    CrossrefPubMedGoogle Scholar
  • 23 Park CB, Greason KL, Suri RM, Michelena HI, Schaff HV, Sundt III TM. Fate of nonreplaced sinuses of Valsalva in bicuspid aortic valve disease. J Thorac Cardiovasc Surg 2011; 142 (02) 278-284
    CrossrefPubMedGoogle Scholar
  • 24 Mortensen K, Aydin MA, Rybczynski M. , et al. Augmentation index relates to progression of aortic disease in adults with Marfan syndrome. Am J Hypertens 2009; 22 (09) 971-979
    CrossrefPubMedGoogle Scholar
  • 25 Shim CY, Cho IJ, Yang WI. , et al. Central aortic stiffness and its association with ascending aorta dilation in subjects with a bicuspid aortic valve. J Am Soc Echocardiogr 2011; 24 (08) 847-852
    CrossrefPubMedGoogle Scholar
  • 26 Aydin A, Desai N, Bernhardt AM. , et al. Ascending aortic aneurysm and aortic valve dysfunction in bicuspid aortic valve disease. Int J Cardiol 2013; 164 (03) 301-305
    CrossrefPubMedGoogle Scholar
  • 27 Keane MG, Wiegers SE, Plappert T, Pochettino A, Bavaria JE, Sutton MG. Bicuspid aortic valves are associated with aortic dilatation out of proportion to coexistent valvular lesions. Circulation 2000; 102 (19) (Suppl. 03) III35-III39
    CrossrefPubMedGoogle Scholar
  • 28 Hillebrand M, Koschyk D, ter Hark P. , et al. Sensitivity and specificity of routine echocardiography for bicuspid aortic valve disease: Retrospective study, systematic review and meta-analysis. in preparation
    PubMed
  • 29 Nejatian A, Yu J, Geva T, White MT, Prakash A. Aortic measurements in patients with aortopathy are larger and more reproducible by cardiac magnetic resonance compared with echocardiography. Pediatr Cardiol 2015; 36 (08) 1761-1773
    CrossrefPubMedGoogle Scholar
  • 30 Flachskampf FA, Badano L, Daniel WG. , et al; European Association of Echocardiography; Echo Committee of the European Association of Cardiothoracic Anaesthesiologists. Recommendations for transoesophageal echocardiography: update 2010. Eur J Echocardiogr 2010; 11 (07) 557-576
    CrossrefPubMedGoogle Scholar
  • 31 Suzuki T, Bossone E, Sawaki D. , et al. Biomarkers of aortic diseases. Am Heart J 2013; 165 (01) 15-25
    CrossrefPubMedGoogle Scholar
  • 32 Trimarchi S, Sangiorgi G, Sang X. , et al. In search of blood tests for thoracic aortic diseases. Ann Thorac Surg 2010; 90 (05) 1735-1742
    CrossrefPubMedGoogle Scholar
  • 33 Branchetti E, Bavaria JE, Grau JB. , et al. Circulating soluble receptor for advanced glycation end product identifies patients with bicuspid aortic valve and associated aortopathies. Arterioscler Thromb Vasc Biol 2014; 34 (10) 2349-2357
    CrossrefPubMedGoogle Scholar
  • 34 Drapisz S, Góralczyk T, Jamka-Miszalski T, Olszowska M, Undas A. Nonstenotic bicuspid aortic valve is associated with elevated plasma asymmetric dimethylarginine. J Cardiovasc Med (Hagerstown) 2013; 14 (06) 446-452
    CrossrefPubMedGoogle Scholar
  • 35 Ikonomidis JS, Ivey CR, Wheeler JB. , et al. Plasma biomarkers for distinguishing etiologic subtypes of thoracic aortic aneurysm disease. J Thorac Cardiovasc Surg 2013; 145 (05) 1326-1333
    CrossrefPubMedGoogle Scholar
  • 36 Black KM, Masuzawa A, Hagberg RC. , et al. Preliminary biomarkers for identification of human ascending thoracic aortic aneurysm. J Am Heart Assoc 2013; 2 (06) e000138
    CrossrefPubMedGoogle Scholar
  • 37 Grewal N, Gittenberger-de Groot AC, DeRuiter MC. , et al. Bicuspid aortic valve: phosphorylation of c-Kit and downstream targets are prognostic for future aortopathy. Eur J Cardiothorac Surg 2014; 46 (05) 831-839
    CrossrefPubMedGoogle Scholar
  • 38 Apte SS, Parks WC. Metalloproteinases: a parade of functions in matrix biology and an outlook for the future. Matrix Biol 2015; 44–46: 1-6
    PubMedGoogle Scholar
  • 39 Longo GM, Xiong W, Greiner TC, Zhao Y, Fiotti N, Baxter BT. Matrix metalloproteinases 2 and 9 work in concert to produce aortic aneurysms. J Clin Invest 2002; 110 (05) 625-632
    CrossrefPubMedGoogle Scholar
  • 40 McMillan WD, Pearce WH. Increased plasma levels of metalloproteinase-9 are associated with abdominal aortic aneurysms. J Vasc Surg 1999; 29 (01) 122-127 , discussion 127–129
    CrossrefPubMedGoogle Scholar
  • 41 Monaco M, Stassano P, Di Tommaso L, Iannelli G. Response of plasma matrix metalloproteinases and tissue inhibitor of metalloproteinases to stent-graft surgery for descending thoracic aortic aneurysms. J Thorac Cardiovasc Surg 2007; 134 (04) 925-931
    CrossrefPubMedGoogle Scholar
  • 42 Koullias GJ, Ravichandran P, Korkolis DP, Rimm DL, Elefteriades JA. Increased tissue microarray matrix metalloproteinase expression favors proteolysis in thoracic aortic aneurysms and dissections. Ann Thorac Surg 2004; 78 (06) 2106-2110 , discussion 2110–2111
    CrossrefPubMedGoogle Scholar
  • 43 Schmoker JD, McPartland KJ, Fellinger EK. , et al. Matrix metalloproteinase and tissue inhibitor expression in atherosclerotic and nonatherosclerotic thoracic aortic aneurysms. J Thorac Cardiovasc Surg 2007; 133 (01) 155-161
    CrossrefPubMedGoogle Scholar
  • 44 Boyum J, Fellinger EK, Schmoker JD. , et al. Matrix metalloproteinase activity in thoracic aortic aneurysms associated with bicuspid and tricuspid aortic valves. J Thorac Cardiovasc Surg 2004; 127 (03) 686-691
    CrossrefPubMedGoogle Scholar
  • 45 Wang Y, Wu B, Dong L, Wang C, Wang X, Shu X. Circulating matrix metalloproteinase patterns in association with aortic dilatation in bicuspid aortic valve patients with isolated severe aortic stenosis. Heart Vessels 2016; 31 (02) 189-197
    CrossrefPubMedGoogle Scholar
  • 46 LeMaire SA, Wang X, Wilks JA. , et al. Matrix metalloproteinases in ascending aortic aneurysms: bicuspid versus trileaflet aortic valves. J Surg Res 2005; 123 (01) 40-48
    CrossrefPubMedGoogle Scholar
  • 47 Mohamed SA, Noack F, Schoellermann K. , et al. Elevation of matrix metalloproteinases in different areas of ascending aortic aneurysms in patients with bicuspid and tricuspid aortic valves. ScientificWorldJournal 2012; 2012: 806261
    PubMedGoogle Scholar
  • 48 Ikonomidis JS, Ruddy JM, Benton Jr SM. , et al. Aortic dilatation with bicuspid aortic valves: cusp fusion correlates to matrix metalloproteinases and inhibitors. Ann Thorac Surg 2012; 93 (02) 457-463
    CrossrefPubMedGoogle Scholar
  • 49 Rabkin SW. Differential expression of MMP-2, MMP-9 and TIMP proteins in thoracic aortic aneurysm - comparison with and without bicuspid aortic valve: a meta-analysis. Vasa 2014; 43 (06) 433-442
    CrossrefPubMedGoogle Scholar
  • 50 Tzemos N, Lyseggen E, Silversides C. , et al. Endothelial function, carotid-femoral stiffness, and plasma matrix metalloproteinase-2 in men with bicuspid aortic valve and dilated aorta. J Am Coll Cardiol 2010; 55 (07) 660-668
    CrossrefPubMedGoogle Scholar
  • 51 Padang R, Bannon PG, Jeremy R. , et al. The genetic and molecular basis of bicuspid aortic valve associated thoracic aortopathy: a link to phenotype heterogeneity. Ann Cardiothorac Surg 2013; 2 (01) 83-91
    PubMedGoogle Scholar
  • 52 Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116 (02) 281-297
    CrossrefPubMedGoogle Scholar
  • 53 Boon RA, Dimmeler S. MicroRNAs and aneurysm formation. Trends Cardiovasc Med 2011; 21 (06) 172-177
    CrossrefPubMedGoogle Scholar
  • 54 Liu G, Huang Y, Lu X. , et al. Identification and characteristics of microRNAs with altered expression patterns in a rat model of abdominal aortic aneurysms. Tohoku J Exp Med 2010; 222 (03) 187-193
    CrossrefPubMedGoogle Scholar
  • 55 Elia L, Quintavalle M, Zhang J. , et al. The knockout of miR-143 and -145 alters smooth muscle cell maintenance and vascular homeostasis in mice: correlates with human disease. Cell Death Differ 2009; 16 (12) 1590-1598
    CrossrefPubMedGoogle Scholar
  • 56 Liao M, Zou S, Weng J. , et al. A microRNA profile comparison between thoracic aortic dissection and normal thoracic aorta indicates the potential role of microRNAs in contributing to thoracic aortic dissection pathogenesis. J Vasc Surg 2011; 53 (05) 1341-1349.e3
    CrossrefPubMedGoogle Scholar
  • 57 Jones JA, Stroud RE, O'Quinn EC. , et al. Selective microRNA suppression in human thoracic aneurysms: relationship of miR-29a to aortic size and proteolytic induction. Circ Cardiovasc Genet 2011; 4 (06) 605-613
    CrossrefPubMedGoogle Scholar
  • 58 Boon RA, Seeger T, Heydt S. , et al. MicroRNA-29 in aortic dilation: implications for aneurysm formation. Circ Res 2011; 109 (10) 1115-1119
    CrossrefPubMedGoogle Scholar
  • 59 Small EM, Frost RJ, Olson EN. MicroRNAs add a new dimension to cardiovascular disease. Circulation 2010; 121 (08) 1022-1032
    CrossrefPubMedGoogle Scholar
  • 60 Pannu H, Fadulu VT, Chang J. , et al. Mutations in transforming growth factor-beta receptor type II cause familial thoracic aortic aneurysms and dissections. Circulation 2005; 112 (04) 513-520
    CrossrefPubMedGoogle Scholar
  • 61 Matt P, Habashi J, Carrel T, Cameron DE, Van Eyk JE, Dietz HC. Recent advances in understanding Marfan syndrome: should we now treat surgical patients with losartan?. J Thorac Cardiovasc Surg 2008; 135 (02) 389-394
    CrossrefPubMedGoogle Scholar
  • 62 Hillebrand M, Millot N, Sheikhzadeh S. , et al. Total serum transforming growth factor-β1 is elevated in the entire spectrum of genetic aortic syndromes. Clin Cardiol 2014; 37 (11) 672-679
    CrossrefPubMedGoogle Scholar
  • 63 Vignaud H, Cullin C, Bouchecareilh M. Alpha-1 antitrypsin deficiency: a model of alteration of protein homeostasis or proteostasis [in French]. Rev Mal Respir 2015; 32 (10) 1059-1071
    CrossrefPubMedGoogle Scholar
  • 64 Schachner T, Golderer G, Sarg B. , et al. The amounts of alpha 1 antitrypsin protein are reduced in the vascular wall of the acutely dissected human ascending aorta. Eur J Cardiothorac Surg 2010; 37 (03) 684-690
    CrossrefPubMedGoogle Scholar
  • 65 Kilickesmez KO, Abaci O, Kocas C. , et al. Dilatation of the ascending aorta and serum alpha 1-antitrypsin level in patients with bicuspid aortic valve. Heart Vessels 2012; 27 (04) 391-397
    CrossrefPubMedGoogle Scholar
  • 66 Vizzardi E, Corda L, Pezzali N. , et al. Elastic properties of the ascending aorta in patients with α1-antitrypsin deficiency (Z homozygotes). Heart 2012; 98 (18) 1354-1358
    CrossrefPubMedGoogle Scholar
  • 67 Böger RH. Asymmetric dimethylarginine (ADMA) and cardiovascular disease: insights from prospective clinical trials. Vasc Med 2005; 10 (02) (Suppl. 01) S19-S25
    CrossrefPubMedGoogle Scholar
  • 68 Böger RH, Sullivan LM, Schwedhelm E. , et al. Plasma asymmetric dimethylarginine and incidence of cardiovascular disease and death in the community. Circulation 2009; 119 (12) 1592-1600
    CrossrefPubMedGoogle Scholar
  • 69 Schnabel R, Blankenberg S, Lubos E. , et al. Asymmetric dimethylarginine and the risk of cardiovascular events and death in patients with coronary artery disease: results from the AtheroGene Study. Circ Res 2005; 97 (05) e53-e59
    CrossrefPubMedGoogle Scholar
  • 70 Hofmann MA, Drury S, Fu C. , et al. RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell 1999; 97 (07) 889-901
    CrossrefPubMedGoogle Scholar
  • 71 Yan SD, Zhu H, Zhu A. , et al. Receptor-dependent cell stress and amyloid accumulation in systemic amyloidosis. Nat Med 2000; 6 (06) 643-651
    CrossrefPubMedGoogle Scholar
  • 72 Yan SF, Ramasamy R, Schmidt AM. The RAGE axis: a fundamental mechanism signaling danger to the vulnerable vasculature. Circ Res 2010; 106 (05) 842-853
    CrossrefPubMedGoogle Scholar
  • 73 Cuccurullo C, Iezzi A, Fazia ML. , et al. Suppression of RAGE as a basis of simvastatin-dependent plaque stabilization in type 2 diabetes. Arterioscler Thromb Vasc Biol 2006; 26 (12) 2716-2723
    CrossrefPubMedGoogle Scholar
  • 74 Schmidt AM, Yan SD, Yan SF, Stern DM. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest 2001; 108 (07) 949-955
    CrossrefPubMedGoogle Scholar
  • 75 Zhang F, Kent KC, Yamanouchi D. , et al. Anti-receptor for advanced glycation end products therapies as novel treatment for abdominal aortic aneurysm. Ann Surg 2009; 250 (03) 416-423
    CrossrefPubMedGoogle Scholar
  • 76 Hofmann Bowman M, Wilk J, Heydemann A. , et al. S100A12 mediates aortic wall remodeling and aortic aneurysm. Circ Res 2010; 106 (01) 145-154
    CrossrefPubMedGoogle Scholar
  • 77 Das D, Gawdzik J, Dellefave-Castillo L. , et al. S100A12 expression in thoracic aortic aneurysm is associated with increased risk of dissection and perioperative complications. J Am Coll Cardiol 2012; 60 (08) 775-785
    CrossrefPubMedGoogle Scholar
  • 78 Lotze MT, Tracey KJ. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol 2005; 5 (04) 331-342
    CrossrefPubMedGoogle Scholar
  • 79 Kohno T, Anzai T, Kaneko H. , et al. High-mobility group box 1 protein blockade suppresses development of abdominal aortic aneurysm. J Cardiol 2012; 59 (03) 299-306
    CrossrefPubMedGoogle Scholar
  • 80 Yamagishi S, Adachi H, Nakamura K. , et al. Positive association between serum levels of advanced glycation end products and the soluble form of receptor for advanced glycation end products in nondiabetic subjects. Metabolism 2006; 55 (09) 1227-1231
    CrossrefPubMedGoogle Scholar